Kuwait Pharmaceutical Import and Registration: A 2026 Guide for UK Exporters

Kuwait is a high-value, import-dependent pharmaceutical market. With effectively all of its finished medicines sourced from abroad, a well-funded public health system, and tertiary hospitals that draw on the same UK and European supply base as the rest of the Gulf, it is a market that rewards exporters who understand its rules and frustrates those who do not. For UK suppliers of UK-licensed, MHRA-authorised medicines, the opportunity is real, but it runs entirely through one regulator and one mandatory local structure.

This guide is written for hospital procurement teams, Ministry of Health buyers, and licensed distributors in Kuwait who source UK-licensed medicines, and for the UK exporters who serve them. It sets out who regulates the market, the registration and import-permit pathway, the documents you will be asked for, how UK-licensed supply maps onto Kuwait's requirements, the special-import route for a product that is not yet registered, and the practical pitfalls that delay shipments. Where specific fees, article numbers or exact timelines are not publicly settled, we describe the process in correct general terms rather than inventing detail, and we recommend confirming the current position with the appointed local agent.

The Regulator: Kuwait MOH and PHMRCA

Pharmaceutical regulation in Kuwait sits within the Ministry of Health, through its drug and food control function. The body that handles medicine registration and control is the Pharmaceutical and Herbal Medicines Registration and Control Administration, commonly abbreviated to PHMRCA. The legal foundation is the Kuwait Pharmacy Law, updated through ministerial decrees, most notably Ministerial Decree No. 361 of 2019, which restated the registration framework and aligned dossier requirements with Gulf Health Council guidance.

The principle is simple and strictly enforced: a medicine cannot lawfully enter the Kuwaiti market unless it is registered with the administration and imported by a locally licensed agent. The administration reviews registration dossiers submitted in Common Technical Document (CTD) format, may request a Good Manufacturing Practice inspection of the manufacturing site, sets pricing, and issues the registration certificate. Once granted, a product registration in Kuwait is valid for five years and must be renewed around six months before it expires.

Kuwait also participates in the Gulf Health Council centralised drug registration procedure, which allows a single dossier to be reviewed for approval across all six GCC states. A product that already carries GCC central approval is in a stronger position when completing national registration in Kuwait, although the national Ministry of Health step, local agent, pricing and import licensing still apply at country level. For exporters weighing one market against several, our regulator comparison tool sets Kuwait alongside the SFDA, MOHAP and other Gulf and wider authorities.

The Local Agent: A Non-Negotiable First Step

No UK exporter can register a product or clear a shipment into Kuwait on its own. Every imported medicine must be represented by a local agent: a Kuwaiti company licensed by both the Ministry of Commerce and the Ministry of Health to import and distribute medicines. This is not an administrative formality. The local agent is the legal counterparty inside Kuwait and carries real responsibility across the product life cycle.

The local agent typically:

• Holds the product registration and the import licence in Kuwait
• Compiles and submits the CTD registration dossier to the PHMRCA
• Applies for the shipment-level import permit for each consignment
• Manages pricing submissions, variations and renewals
• Carries pharmacovigilance and post-market reporting duties locally
• Acts as the point of contact with the Ministry of Health

The Ministry of Health generally expects the foreign principal to grant the local agent exclusive distribution rights for the product, formalised through a legalised letter of appointment. Choosing the agent well matters: the agent's hospital relationships, Ministry standing, storage and cold chain capacity, and operational discipline all shape how quickly a UK-licensed product reaches the ward. Selecting on the basis of the lowest fee alone is one of the more expensive mistakes an exporter can make.

Routes to Supply: Full Registration and Special Import

There are two principal ways a UK-licensed medicine reaches a Kuwaiti hospital, and most exporters will use both at different times.

1. Full marketing authorisation (registration)

This is the route for any product intended to be supplied routinely and at volume. The local agent submits a full CTD dossier to the PHMRCA, the administration reviews it, pricing is agreed, and a five-year registration is granted. Registration is the prerequisite for ongoing hospital tender supply and for inclusion in routine Ministry of Health procurement. It is the right route when there is a sustained, predictable demand for the product.

2. Special import for an unregistered product

Where a UK-licensed medicine is not yet registered in Kuwait but a genuine clinical need exists, Kuwait operates a special-import route. Kuwait's Ministry of Health has issued resolutions governing the supply of non-registered medical products, and the framework permits a medicine that is registered with a recognised international regulator, and for which there is no registered local alternative, to be brought in against a documented requirement at the request of the relevant Ministry of Health authority.

It is important to frame this route correctly. This is the buyer's in-country regulatory mechanism for importing a UK-licensed, MHRA-authorised product that simply does not yet hold a Kuwaiti registration. The Kuwaiti hospital or institution, acting through its licensed local agent, applies to the Ministry of Health for a specific authorisation against a named clinical need. The UK supplier's job is to provide the country of origin documentation that supports the agent's application: the CPP, the certificate of analysis, and batch release evidence. This is a pathway to import a properly licensed product against a recognised need. It is not a route for supplying any unlicensed or special-manufactured product, and it should never be presented as such.

The special-import route is the natural fit for specialty oncology lines, rare disease therapies, and shortage cover, where no Kuwaiti registration exists and the clinical need is immediate. Because it is processed against an individual authorisation rather than a full dossier review, it is considerably faster than full registration. Our named patient supply service describes how the UK side of this is handled, and our UK pharmaceutical exporter to Kuwait page covers the commercial entry points.

Documents Kuwait Typically Requires

The registration dossier follows the CTD structure, with Kuwait-specific supplements. The table below sets out the core documents a UK-licensed product is usually asked for. Exact requirements are confirmed by the local agent against current PHMRCA guidance, which is periodically updated.

Two documents deserve particular attention. The first is the CPP. The PHMRCA expects a current CPP issued by the MHRA in WHO format, naming the specific manufacturing site. UK manufacturers obtain it through the MHRA Export Certificate service, and turnaround is not instant, so the CPP request should be planned into the timeline well before the intended filing window. The second is legalisation: country of origin documents such as the CPP, GMP certificate and letter of appointment generally need to be legalised, in practice through the Kuwait embassy in London, before they will be accepted. Skipping or under-budgeting the legalisation step is a frequent cause of dossier rejection. Our companion resource on UK pharmaceutical import documentation walks through the full export pack in detail.

The Import Permit and Batch Flow

Registration grants the right to market a product; it does not, by itself, move stock. Each consignment into Kuwait requires a shipment-level import permit, applied for by the local agent and tied to the registered product. Alongside the permit, every batch must travel with its Qualified Person batch release certificate and certificate of analysis, so that the documentation presented at the Kuwaiti border matches the physical goods.

For a UK exporter that is not the manufacturer, this means coordinating with the manufacturer's Qualified Person to obtain batch release in advance of despatch, and assembling a consistent export pack for every shipment. The packing list, commercial invoice (often chamber-attested), certificate of origin, batch documentation and import permit reference need to align precisely. Mismatches between the permit, the invoice and the physical consignment are among the most common reasons stock is held at the border.

Cold Chain and GDP for Kuwait

A meaningful share of UK-licensed exports to Kuwait, including specialty oncology and other temperature-sensitive lines, travel under cold chain. Kuwait's summer ambient temperatures are extreme, which raises the stakes for any 2 to 8 degree Celsius product. UK exporters supplying these lines should expect to demonstrate:

• MHRA-validated temperature-controlled storage at the specified range before despatch
• Qualified passive or active shipping containers, validated against the high-ambient Heathrow to Kuwait route profile
• A calibrated temperature data logger accompanying the consignment end to end
• Stability data that supports the transit conditions actually experienced
• A GDP-compliant chain from UK warehouse through Heathrow cargo to Kuwait International Airport and on to the agent or hospital

Heathrow to Kuwait is a direct routing of roughly six and a half hours, with multiple daily services, so same-day despatch and rapid delivery are achievable for urgent and shortage consignments. A documented temperature-excursion handling procedure, agreed with the consignee in advance, prevents a minor logger deviation from turning into a quarantined shipment. Our services overview sets out how Euro Biom operates the UK supply leg under GDP.

Common Pitfalls to Avoid

Across Gulf registration and import projects, the same issues recur. For Kuwait specifically, watch for the following.

1. Treating the local agent as an afterthought

Nothing moves without an appointed, licensed local agent. Identify and appoint the agent before, not after, you start preparing documentation, and grant the exclusivity the Ministry expects.

2. Under-budgeting legalisation

The CPP, GMP certificate and letter of appointment generally require embassy legalisation. This takes time and cost that exporters routinely underestimate. Build it into the plan from day one.

3. An out-of-date or wrong-format CPP

The CPP must be a current MHRA WHO-format certificate naming the correct manufacturing site. Internal export certificates that are not in WHO format will not satisfy the PHMRCA.

4. Arabic labelling errors

Carton, label and patient information must meet Kuwait's Arabic labelling rules. Have the labelling pack reviewed locally before submission and before each despatch.

5. Climatic-zone stability gaps

Stability data must support Kuwait's hot, humid climatic zone. Data generated only for temperate conditions may be challenged; confirm the requirement with the agent early.

6. Misframing the special-import route

The special-import pathway is for importing a UK-licensed product against a documented clinical need where no registered alternative exists. It is a buyer-side mechanism, applied for by the institution through its agent, and should never be confused with supplying unlicensed product.

How Euro Biom Supports Kuwait Supply

Euro Biom is a UK MHRA-licensed pharmaceutical wholesale exporter, holding Wholesale Dealer Authorisation WDA(H) 59239. We supply UK-licensed, MHRA-authorised finished medicines. We do not manufacture, and we are not a regulatory consultancy. What we do is operate the UK supply leg of a compliant export into Kuwait, working alongside the manufacturer, the marketing authorisation holder, the Kuwaiti importer and the licensed local agent.

For Kuwait-bound supply, our role typically covers:

• UK-side documentation. Coordinating MHRA CPP procurement with the manufacturer or MA holder, GMP certificate retrieval, and the GDP-compliant export pack of CoA, batch release, packing list and chamber-attested commercial invoice, ready for legalisation.
• Cold chain logistics from Heathrow. GDP-validated temperature-controlled storage, qualified shipping containers, calibrated data loggers and direct Heathrow despatch to Kuwait International Airport.
• Special-import support. Supplying the country of origin documentation that a Kuwaiti hospital and its local agent need to support a Ministry of Health authorisation for a UK-licensed product against a documented clinical need.
• Shortage cover. Rapid response where Heathrow proximity, MHRA-licensed inventory and same-day despatch are decisive for a Kuwaiti hospital facing a supply gap.

For the commercial entry points to this market, see our UK pharmaceutical exporter to Kuwait page. For the wider Gulf picture, the regulator comparison tool places Kuwait next to its neighbours, and the UK import documentation guide details the full export pack.